SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001328143-21-000053
Filing Date
2021-06-04
Accepted
2021-06-04 16:02:38
Documents
12
Period of Report
2021-06-02
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K adms-20210602.htm   iXBRL 8-K 46544
  Complete submission text file 0001328143-21-000053.txt   189980

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20210602.xsd EX-101.SCH 1914
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20210602_lab.xml EX-101.LAB 26042
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20210602_pre.xml EX-101.PRE 14071
5 EXTRACTED XBRL INSTANCE DOCUMENT adms-20210602_htm.xml XML 10978
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36399 | Film No.: 21996406
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences